Clinical trials: Monoclonal Antibody
Gastroenteritis
Omalizumab to Treat Eosinophilic Gastroenteritis
This study will evaluate the safety and usefulness of omalizumab (anti-IgE, Xolair) in reducing eosinophil counts and improving symptoms in patients with eosinophilic gastroenteritis (EG).
- Trial name
- NCT00084097
- Testing
- Omalizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dermatitis, Atopic
A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of MG-K10 monotherapy in adolescents with moderate-to-severe atopic dermatitis (AD)
- Trial name
- NCT07540442
- Testing
- MG-K10 Injection (Humanized Monoclonal Antibody)
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Breast Neoplasm
Clinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib
A retrospective, observational, not EPA, multicenter study to evaluate the Clinical Benefit of Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With…
- Trial name
- TRASTYVERE (NCT02056080)
- Where
- 11 sites in Spain
- Volunteers
- 111 people
- Sponsor
- MedSIR
Arthritis, Psoriatic
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
The purpose of this study is to evaluate the efficacy (improvement of signs and symptoms) and safety of ustekinumab in patients with psoriatic arthritis.
- Trial name
- NCT01077362
- Testing
- ustekinumab 45 mg, ustekinumab 90 mg
- Where
- 80 sites in United States, Austria and 8 more
- Volunteers
- 312 people
- Sponsor
- Janssen Research & Development, LLC
COVID-19
Study to Evaluate the Safety and Efficacy of a Monoclonal Antibody Cocktail for the Prevention of COVID-19
This is a Phase 2/3, randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety, tolerability, and efficacy of ADM03820 to prevent symptomatic COVID-19 in adult subjects (≥ 18 years of age).
- Trial name
- NCT05142527
- Testing
- ADM03820
- Volunteers
- healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Malaria,Falciparum
Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics of TB31F
This phase 1 study aims to assess the safety and tolerability of monoclonal antibody TB31F administered intravenously or subcutaneously at escalating dose levels in healthy, malaria naïve, adults.
- Trial name
- TB31F (NCT04238689)
- Testing
- TB31F
- Where
- Netherlands
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Advanced Biliary Tract Cancer
A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer
This study is a clinical study to explore the efficacy and safety of BL-B01D1+PD-1/PD-L1 monoclonal antibody in patients with advanced biliary tract cancer.
- Trial name
- NCT06978114
- Testing
- BL-B01D1, Pembrolizumab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Leukemia, Hematopoetic Stem Cell Transplantation
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
This study aims to improve the treatment of blood cancer by using exercise to collect healthier immune cells from donors. Allogeneic adoptive cell therapy is a treatment where immune cells from a healthy donor are given to a…
- Conditions
- Leukemia, Hematopoetic Stem Cell Transplantation, Donor Lymphocyte Infusion, CAR T-Cell Therapy
- Trial name
- Allo-X (NCT06643221)
- Testing
- Exercise, Isoproterenol, Bisoprolol Fumarate Tablet 10 mg
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Liver Transplant Rejection
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension
This was a multicenter, open-label, active-controlled study to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of two CFZ533 maintenance doses in de novo liver transplant recipients.
- Trial name
- CONTRAIL I (NCT03781414)
- Testing
- CFZ533, Tacrolimus - MMF - corticosteroids
- Where
- 29 sites in United States, Argentina and 8 more
- Volunteers
- 129 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
Effect of Recombinant FVIII in Healthy Male Subjects Treated With TB-402
Single administration of recombinant FVIII/placebo in healthy male subjects who have been treated with a single dose of anti-factor VIII antibody, TB-402
- Trial name
- NCT00612417
- Where
- Denmark
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- ThromboGenics
Effect Increased, Safety Issues
Bronchoscopic Microwave Intervention Treatment in Advanced Central NSCLC
A randomized, prospective study of the efficacy and safety of the first-line treatment in advanced central non-small cell lung cancer patients by anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy versus anti-PD-1 / PD-L1…
- Trial name
- NCT04360655
- Testing
- bronchoscopic microwave intervention, anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
- Volunteers
- 50 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia
MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma
Biological therapies, such as MDX-010, work in different ways to stimulate the immune system and stop cancer cells from growing.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Trial name
- NCT00089076
- Testing
- ipilimumab, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer
This study will evaluate the effectiveness of the drug bevacizumab, in combination with doxorubicin and docetaxel, in improving survival of patients with inflammatory breast cancer or locally advanced breast cancer.
- Trial name
- NCT00016549
- Testing
- Bevacizumab
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
This is a randomised, open-label, multicenter, phase III study for adult de novo Ph+ ALL patients based on the combination of Ponatinib with Blinatumomab.
- Conditions
- Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult, Philadelphia-Positive ALL
- Trial name
- NCT04722848
- Testing
- Ponatinib + Blinatumomab, Chemotherapy + Imatinib
- Where
- 15 sites in Italy
- Volunteers
- 236 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Lymphoma
Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00004874
- Testing
- tositumomab and iodine I 131 tositumomab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Nebraska
Stiff Person Syndrome
Rituximab to Treat Stiff Person Syndrome
This study will test whether rituximab (RITUXAN (Trademark)) can relieve symptoms of stiff person syndrome (SPS), a progressive disease that causes stiffness of the muscles and muscle spasms induced by unexpected noises, touches…
- Trial name
- NCT00091897
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Plasmodium Falciparum Infection, Malaria
Anti-malaria MAb in Kenyan Children
The purpose of this study is to evaluate the safety and tolerability of one-time subcutaneous (SC) administration of monoclonal antibody (MAb) L9LS in healthy Kenyan children aged 5 months to 10 years, as well as the protective…
- Trial name
- NCT05400655
- Testing
- L9LS
- Where
- Kenya
- Volunteers
- 912 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
This phase I trial studies the side effects and best dose of cixutumumab when given together with everolimus and octreotide acetate in treating patients with advanced low- or intermediate-grade neuroendocrine cancer.
- Conditions
- Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Pancreatic Glucagonoma
- Trial name
- NCT01204476
- Testing
- Cixutumumab, Everolimus, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Diabetic Polyneuropathy
A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy
The main purpose of this study is to compare the change in pain intensity during treatment with a CGRP monoclonal antibody (eptinezumab) compared with placebo treatment in patients with painful diabetic polyneuropathy (DPN).
- Trial name
- NCT05937152
- Testing
- Eptinezumab
- Where
- 3 sites in United States, Denmark
- Sponsor
- Mayo Clinic
Advanced Solid Tumor, Lymphoma
A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.
This is first in human (FIH) study to a) evaluate the safety and tolerability profile of GRC54276, b) determine the maximum tolerated dose (MTD) and recommended Phase 2 doses (RP2D), and c) pharmacokinetic profile of GRC54276…
- Trial name
- NCT05878691
- Testing
- GRC 54276, GRC 54276 + Pembrolizumab, GRC 54276 + Atezolizumab
- Where
- 18 sites in United States, India
- Volunteers
- 320 people
- Sponsor
- Glenmark Specialty S.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.